^
Association details:
| Biomarker: | AR positive |
|---|---|
| Cancer: | Salivary Gland Cancer |
| Drug: | Eligard (leuprolide acetate) (GnRH agonist) + bicalutamide (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma
Excerpt:
This study suggests that CAB has equivalent efficacy and less toxicity for patients with AR-positive RM or unresectable LA SGC compared with conventional chemotherapy, which warrants further study.
DOI:
10.1093/annonc/mdx771
